Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
ABP | NDAQ
Overview
Corporate Details
- ISIN(s):
- US04845A1088 (+2 more)
- LEI:
- Country:
- United States of America
- Address:
- 6 ST JOHNS LANE, FLOOR 5, 10013 NEW YORK
- Website:
- https://abpro.co/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Abpro Holdings, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation antibody therapeutics for severe and life-threatening diseases. The company focuses on advancing a pipeline of novel antibody constructs, with primary applications in immuno-oncology and ophthalmology. Abpro leverages its proprietary DiversImmune® and MultiMab platforms to create advanced therapies aimed at improving the lives of patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Abpro Holdings, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Abpro Holdings, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Abpro Holdings, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
